TABLE 2

Twelve-Week Overall Response and CR Rates

Response rateAll patients131I-Tositumomab (n = 18)90Y-Ibritumomab tiuxetan (n = 12)P*
Overall (n)14 (47%)8 (44%)6 (50%)1.00
Complete (n)4 (13%)3 (17%)1 (8%)0.63

  • ↵* Fisher exact test P value: 131I-tositumomab vs. 90Y-ibritumomab tiuxetan.